Literature DB >> 8247921

Possible interaction between warfarin and fluconazole.

K R Gericke1.   

Abstract

Fluconazole is a triazole antifungal agent reported to have a low affinity for human cytochrome P-450, and thus would not be expected to interact with drugs metabolized through the cytochrome P-450 system, including phenytoin, cyclosporine, and warfarin. A potential interaction between warfarin and fluconazole occurred in a 39-year-old man with chronic renal insufficiency. He was receiving anticoagulant therapy for a lower extremity thrombus and oral fluconazole 50 mg/day for a fungal urinary tract infection. After attaining consistent international normalized ratio (INR) values between 2.0 and 2.7 with warfarin, the INR increased to 5.2 four days after fluconazole was started, despite decreasing the dosage of warfarin. There were no changes in the patient's other medications, and the INR decreased to 1.5 on discontinuation of fluconazole. The possible mechanism of an interaction may be dose-related inhibition of warfarin metabolism, and may be more pronounced in patients with decreased renal clearance of fluconazole.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8247921

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  10 in total

Review 1.  Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Authors:  K Venkatakrishnan; L L von Moltke; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

Review 2.  Systemic antifungal agents. Drug interactions of clinical significance.

Authors:  E Albengres; H Le Louët; J P Tillement
Journal:  Drug Saf       Date:  1998-02       Impact factor: 5.606

Review 3.  Fluconazole. An update of its antimicrobial activity, pharmacokinetic properties, and therapeutic use in vaginal candidiasis.

Authors:  C M Perry; R Whittington; D McTavish
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

Review 4.  Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients.

Authors:  K L Goa; L B Barradell
Journal:  Drugs       Date:  1995-10       Impact factor: 9.546

Review 5.  Clinically important drug interactions with anticoagulants. An update.

Authors:  S Harder; P Thürmann
Journal:  Clin Pharmacokinet       Date:  1996-06       Impact factor: 6.447

Review 6.  The enzymatic basis of drug-drug interactions with systemic triazole antifungals.

Authors:  Yasmine Nivoix; Dominique Levêque; Raoul Herbrecht; Jean-Claude Koffel; Laurence Beretz; Genevieve Ubeaud-Sequier
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

7.  Challenges in achieving a target international normalized ratio for deep vein thrombosis among HIV-infected patients with tuberculosis: a case series.

Authors:  C Sekaggya; D Nalwanga; A Von Braun; R Nakijoba; A Kambugu; J Fehr; M Lamorde; B Castelnuovo
Journal:  BMC Hematol       Date:  2016-06-04

8.  New treatments for vulvovaginal candidiasis.

Authors:  S Faro
Journal:  Infect Dis Obstet Gynecol       Date:  1996

9.  Anastrozole-induced pulmonary cryptococcosis in a patient with early breast cancer: A case report.

Authors:  Min Wei; Yu-Rong Xu; Kui Liu; Peng Wen
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.817

10.  The influence of Javanese turmeric (Curcuma xanthorrhiza) on the pharmacokinetics of warfarin in rats with single and multiple-dose studies.

Authors:  Taofik Rusdiana; Yanni D Mardhiani; Norisca A Putriana; Dolih Gozali; Daisuke Nagano; Takuya Araki; Koujirou Yamamoto
Journal:  Pharm Biol       Date:  2021-12       Impact factor: 3.503

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.